Passage Bio, Inc.
PASG
Rank in Stocks
#28478
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering... Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Share Price
$3.43
Last synced: 2026-11-09
Market Cap
$11.04M
Change (1 day)
-13.71%
Change (1 year)
-55.45%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Passage Bio, Inc. (PASG)
Category
Healthcare
EPS for Passage Bio, Inc. (PASG)
EPS as of June 2026 TTM: $-11.33
According to Passage Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-11.33. At the end of 2025 the company had an EPS of $-14.35, an increase over its 2024 EPS of $-21.44.
EPS history for Passage Bio, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-11.33 | -21.05% |
| 2025 | $-14.35 | -33.07% |
| 2024 | $-21.44 | -42.50% |
| 2023 | $-37.29 | -25.42% |
| 2022 | $-50.00 | -28.07% |
| 2021 | $-69.51 | 20.26% |
| 2020 | $-57.80 | 26.75% |
| 2019 | $-45.60 | 330.19% |
| 2018 | $-10.60 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -238.22% |
US
|
|
| $-7.07 | -37.60% |
US
|
|
| $-5.29 | -53.31% |
AU
|
|
| $12.88 | -213.68% |
BE
|
|
| $21.56 | -290.29% |
NL
|
Questions about Passage Bio, Inc.'s earnings per share (EPS)
What is Passage Bio, Inc.'s earnings per share (EPS)?
Passage Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-11.33, as of Jun 2026.
What was Passage Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Passage Bio, Inc.'s earnings per share (EPS) was $-14.35, compared with $-21.44 in 2024.
How has Passage Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Passage Bio, Inc.'s earnings per share (EPS) was highest in 2025 ($-14.35) and lowest in 2021 ($-69.51).
How does Passage Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Passage Bio, Inc.'s earnings per share (EPS) ($-11.33) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.